XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Summary of Significant Accounting Policies (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
May 08, 2024
USD ($)
Apr. 15, 2024
$ / shares
May 01, 2023
Mar. 31, 2024
shares
Jun. 30, 2024
$ / shares
shares
Mar. 31, 2024
USD ($)
shares
Jun. 30, 2023
shares
Dec. 31, 2023
$ / shares
shares
Class of Stock [Line Items]                
Term of orphan drug exclusivity     7 years          
Ordinary shares, nominal value (in dollars per share) | $ / shares   $ 0.01     $ 0.01     $ 0.01
ADSs, conversion ratio   1            
Preferred shares, shares issued (in shares)         0     5,194,000
Preferred shares, shares outstanding (in shares)         0     5,194,000
Preferred shares                
Class of Stock [Line Items]                
Shares converted (in shares)       (5,194,000)   (5,194,000)    
Ordinary shares                
Class of Stock [Line Items]                
Shares converted (in shares)       5,194,000   5,194,000 12,347,000  
At-The-Market Offering Program                
Class of Stock [Line Items]                
Sales agent commission, as a percent of aggregate gross sales proceeds 3.00%              
Sale of stock, maximum aggregate offering price | $ $ 100,000              
Shares sold in offering (in shares)         0      
Aggregate net proceeds from stock offering | $           $ 9,250    
At-The-Market Offering Program | American Depositary Shares                
Class of Stock [Line Items]                
Shares sold in offering (in shares)           640,000